<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>N4-Palmitoyl-1-beta-D-arabinofuranosylcytosine (PL-AC) was administered p.o. to 199 patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Of 76 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 11 achieved complete remission (CR) and 7 achieved partial remission (PR) </plain></SENT>
<SENT sid="2" pm="."><plain>Of 8 patients with ALL, 2 achieved CR and 1 achieved PR </plain></SENT>
<SENT sid="3" pm="."><plain>Of 3 patients with <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>, 1 achieved CR </plain></SENT>
<SENT sid="4" pm="."><plain>CR was reached with PL-AC at 100-900 mg/day after 5-98 (median 26) days </plain></SENT>
<SENT sid="5" pm="."><plain>Of 50 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 2 achieved CR, 2 showed good response and 7 partial response </plain></SENT>
<SENT sid="6" pm="."><plain>Response was reached with 100-400 mg/day after 13-122 (median 32) days </plain></SENT>
<SENT sid="7" pm="."><plain>Improvement of <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera was observed in 6 of 13 patients, and reduction of <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> was observed in 20 of 23 patients with <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> and <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Of 18 patients with <z:mp ids='MP_0005481'>CML</z:mp>, 1 achieved CR </plain></SENT>
<SENT sid="9" pm="."><plain>Major side effects were GI toxicities and <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>In spite of the disadvantages of the oral form of the drug, such as unpredictable absorption, PL-AC may be useful in the treatment of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, especially that of the aged, a condition for which intensive chemotherapy is not always indicated, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, which do not necessarily require admission to a hospital </plain></SENT>
</text></document>